Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men

被引:36
作者
Bravenboer, N
Holzmann, PJ
ter Maaten, JC
Stuurman, LM
Roos, JC
Lips, P
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, NL-1007 MB Amsterdam, Netherlands
[2] Acad Hosp, Dept Internal Med, Groningen, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Dept Nucl Med, NL-1007 MB Amsterdam, Netherlands
关键词
growth hormone; growth hormone deficiency; BMD; bone metabolism; histomorphometry;
D O I
10.1359/JBMR.050613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Long-term GH treatment in GH-deficient men resulted in a continuous increase in bone turnover as shown by histomorphometry. BMD continuously increased in all regions of interest, but more in the regions with predominantly cortical bone. Introduction: Adults with growth hormone (GH) deficiency have reduced rates of bone turnover and subnormal BMD. GH treatment is effective in enhancing bone turnover as shown by biochemical markers and bone histomorphometric studies. However, it is uncertain whether long-term treatment will result in higher bone mass. In this study, we present BMD and histomorphometric data on 5 years of GH treatment in GH-deficient men. Materials and Methods: Thirty-eight adult men with childhood onset GH deficiency (20-35 years) were included in the study. Twenty-six of these had multiple pituitary hormone deficiencies and were on stable conventional hormone replacement. BMC (total body) and BMD (lumbar spine and hip) were measured before and after 1, 2, 3, 4, and 5 years of treatment. BMD in various regions of the total body was calculated by computer software (head, trunk, arms, and legs). Transiliac bone biopsies were obtained before and after 1 and 5 years of GH treatment. Results: Total body BMC increased 18% after 5 years of treatment. This increase was observed in all regions of interest: head, 13.7%; trunk, 27.8%; arms, 24.4%; legs, 13.8%. BMD also increased in all separately measured regions: lumbar spine, 9%; femoral neck, 11%; femoral trochanter, 16%. Lumbar spine area significantly increased (p = 0.0002). Histomorphometric data showed increased osteoid surface (p < 0.02), osteoid volume (p < 0.01), and activation frequency (p < 0.006), but trabecular bone volume did not increase significantly. Qualitative assessment of the cortical bone showed endosteal and periosteal bone formation. Conclusions: In conclusion, GH considerably increases BMC after long-term treatment. The combination of BMD and histomorphometric data suggests that GH has a greater effect on cortical than on trabecular bone.
引用
收藏
页码:1778 / 1784
页数:7
相关论文
共 27 条
  • [11] POTENT EFFECT OF RECOMBINANT GROWTH-HORMONE ON BONE-MINERAL DENSITY AND BODY-COMPOSITION IN ADULTS WITH PANHYPOPITUITARISM
    DEGERBLAD, M
    ELGINDY, N
    HALL, K
    SJOBERG, HE
    THOREN, M
    [J]. ACTA ENDOCRINOLOGICA, 1992, 126 (05): : 387 - 393
  • [12] Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
    Hansen, TB
    Brixen, K
    Vahl, N
    Jorgensen, JOL
    Christiansen, JS
    Mosekilde, L
    Hagen, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) : 3352 - 3359
  • [13] EFFECT OF GROWTH-HORMONE REPLACEMENT ON BONE MASS IN ADULTS WITH ADULT-ONSET GROWTH-HORMONE DEFICIENCY
    HOLMES, SJ
    WHITEHOUSE, RW
    SWINDELL, R
    ECONOMOU, G
    ADAMS, JE
    SHALET, SM
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 42 (06) : 627 - 633
  • [14] Skeletal effects of two years of treatment with low physiological doses elf recombinant human growth hormone (GH) in patients with adult-onset GH deficiency
    Janssen, YJH
    Hamdy, NAT
    Frölich, M
    Roelfsema, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) : 2143 - 2148
  • [15] Jockenhovel F, 1996, Eur J Med Res, V1, P377
  • [16] Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
    Johannsson, G
    Rosen, T
    Bosaeus, I
    Sjostrom, L
    Bengtsson, BA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (08) : 2865 - 2873
  • [17] INCREASED BONE-DENSITY AFTER RECOMBINANT HUMAN GROWTH-HORMONE (GH) THERAPY IN ADULTS WITH ISOLATED GH DEFICIENCY
    OHALLORAN, DJ
    TSATSOULIS, A
    WHITEHOUSE, RW
    HOLMES, SJ
    ADAMS, JE
    SHALET, SM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (05) : 1344 - 1348
  • [18] BONE HISTOMORPHOMETRY - STANDARDIZATION OF NOMENCLATURE, SYMBOLS, AND UNITS
    PARFITT, AM
    DREZNER, MK
    GLORIEUX, FH
    KANIS, JA
    MALLUCHE, H
    MEUNIER, PJ
    OTT, SM
    RECKER, RR
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1987, 2 (06) : 595 - 610
  • [19] GROWTH-HORMONE TREATMENT IN ADULTS WITH GH DEFICIENCY - EFFECTS ON NEW BIOCHEMICAL MARKERS OF BONE AND COLLAGEN TURNOVER
    SARTORIO, A
    CONTI, A
    MONZANI, M
    MORABITO, F
    FAGLIA, G
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1993, 16 (11) : 893 - 898
  • [20] THE EFFECT OF GROWTH-HORMONE (GH) THERAPY ON URINARY PYRIDINOLINE CROSS-LINKS IN GH-DEFICIENT ADULTS
    SCHLEMMER, A
    JOHANSEN, JS
    PEDERSEN, SA
    JORGENSEN, JOL
    HASSAGER, C
    CHRISTIANSEN, C
    [J]. CLINICAL ENDOCRINOLOGY, 1991, 35 (06) : 471 - 476